194612-36-7

Basic information

• Product Name: Piperidine, 4-(2-chloroethyl)-1-(phenylmethyl)-
• CAS NO: 194612-36-7
• Molecular Formula: C14H20ClN
• Molecular Weight: 237.772
• Mol File: 194612-36-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Piperidine, 4-(2-chloroethyl)-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperidine, 4-(2-chloroethyl)-1-(phenylmethyl)-(194612-36-7)
• EPA Substance Registry System: Piperidine, 4-(2-chloroethyl)-1-(phenylmethyl)-(194612-36-7)

Safety Data

• Hazardous Substances Data: 194612-36-7(Hazardous Substances Data)

Upstream product

• 76876-70-5 N-benzyl-4-(2-hydroxyethyl)piperidine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 40110-55-2 ethyl 2-(1-benzylpiperidine-4-ylidene)acetate 

Downstream Products

• 86945-25-7 4-(2-aminoethyl)-1-(phenylmethyl)piperidine 
• 1334106-33-0 N-{[5-(2-(1-benzylpiperidin-4-yl)ethoxy)-1-methyl-1H-indol-2-yl]methyl}-N-methylprop-2-yn-1-amine 

Relevant articles and documents

Narciclasine derivative, and preparation and application thereof in preparation of antitumor drugs

The invention provides a narciclasine derivative represented by the following structural formula I, wherein R1 is alkyl, cycloalkyl, benzyl or substituted benzyl, R2 is alkyl, cycloalkyl, benzyl or substituted benzyl, and n is an integer from 1 to 10. The narciclasine derivative is subjected to a tumor cell toxicity killing effect test, and results prove that the narciclasine derivative has strong toxicity killing effects on lung gland tumor cells, intestinal tumor cells, breast tumor cells, liver tumor cells, prostate tumor cells, melanoma tumor cells, endometrial tumor cells and neuroglia tumor cells, so the narciclasine derivative can be used for preparation of antitumor drugs. The invention provides a preparation method of the narciclasine derivative. The narciclasine derivative has a novel side-chain structure, shows excellent inhibitory activity on a variety of tumor cell strains, has drug efficacy better than that of narciclasine, allows toxic and side effects of the compound to be improved, provides new drugs for treatment of malignant tumors, and is of great clinical application value.